SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2012
BIOVEST INTERNATIONAL, INC.
(Exact name of Registrant as Specified in its Charter)
324 South Hyde Park Avenue, Suite 350
Tampa, FL 33606
(Address of Principal Executive Offices; Zip Code)
Registrants telephone number, including area code: (813) 864-2554
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
BIOVEST INTERNATIONAL, INC.
The following information is being furnished under Item 7.01 of Form 8-K, a press release dated January 12, 2012, by the Company, titled Biovest Collaborates with Max Planck Institute to Advance its Hollow Fiber Bioreactors for the Manufacture of Viral Vaccines. A copy of this press release is attached as Exhibit 99.1 to this Form 8-K.
This Current Report on Form 8-K sets forth statements that are not strictly historical in nature constitute forward-looking statements. Such statements include, but are not limited to, statements about BiovaxID®, AutovaxID®, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials, the intent to treat analysis, accelerated approval and all aspects of the regulatory process. Such statements may include, without limitation, statements with respect to the Companys plans, objectives, expectations and intentions, and other statements identified by words such as may, could, would, should, believes, expects, anticipates, estimates, intends, plans, or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements in this Form 8-K are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this Current Report on Form 8-K to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
See the Exhibit Index set forth below for a list of exhibits included with this Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized.
Date: January 12, 2012